Parameters | Survivors | Nonsurvivors | Overall population | P value |
---|---|---|---|---|
Number | 49 | 27 | 76 | – |
Age (years) | 73 (62–78) | 70 (61–78) | 71 (61–78) | 0.765 |
Male, n (%) | 22 (44.9 %) | 15 (55.6 %) | 37 (48.7 %) | 0.792 |
WBC (×109/L) | 14.9 (12.4–16.9) | 13.3 (10.9–17.8) | 14.9 (11.8–17.2) | 0.641 |
Lymphocyte (×109/L) | 0.78 (0.59–1.24) | 0.65 (0.52–0.82) | 0.76 (0.54–1.07) | 0.046 |
SOFA score | 11 (9–12) | 14 (12–17) | 11 (9–14) | <0.001 |
SAPS II | 50 (43–56) | 60 (53–66) | 53 (46–60) | <0.001 |
Percentage of PD-1+/CD4+ T cells (%) | 35.1 (28.5–44.8) | 42.9 (34.9–49.0) | 38.2 (29.2–47.7) | 0.034 |
MFI of PD-1 on CD4+ T cells | 7.0 (5.7–8.9) | 8.8 (7.1–9.6) | 7.5 (6.0–9.4) | 0.036 |
Percentage of PD-1+/CD8+ T cells (%) | 33.0 (24.8–44.3) | 47.1 (30.3–53.9) | 36.5 (27.3–51.3) | 0.032 |
MFI of PD-1 on CD8+ T cells | 5.9 (4.7–8.1) | 7.8 (5.4–9.8) | 6.6 (4.9–8.4) | 0.033 |
Percentage of PD-L1+/CD4+ T cells (%) | 16.4 (8.6–28.4) | 22.1 (12.0–34.0) | 21.0 (9.3–30.6) | 0.295 |
MFI of PD-L1 on CD4+ T cells | 1.9 (1.5–2.0) | 1.8 (1.6–2.2) | 1.8 (1.5–2.0) | 0.961 |
Percentage of PD-L1+/CD8+ T cells (%) | 23.2 (10.8–38.9) | 12.9 (9.9–32.5) | 19.5 (10.3–37.4) | 0.204 |
MFI of PD-L1 on CD8+ T cells | 1.6 (1.4–1.9) | 1.5 (1.4–1.7) | 1.5 (1.4–1.8) | 0.378 |
Percentage of monocytes expressing PD-L1 (%) | 28.9 (17.9–43.6) | 53.9 (31.8–72.9) | 35.9 (20.4–54.7) | 0.001 |
MFI of PD-L1 on monocytes | 8.2 (7.5–9.0) | 9.1 (8.1–11.3) | 8.3 (7.7–9.7) | 0.012 |
Type of infection, n (%) | ||||
Pneumonia | 27 (55.1 %) | 14 (51.9 %) | 41 (53.9 %) | 0.786 |
IAI | 8 (16.3 %) | 3 (11.1 %) | 11 (14.5 %) | 0.781 |
CNSI | 4 (8.2 %) | 2 (7.4 %) | 6 (7.9 %) | 0.743 |
USI | 10 (20.4 %) | 8 (29.6 %) | 18 (23.7 %) | 0.366 |
Number of comorbidities | ||||
≥1, n (%) | 21 (42.9 %) | 18 (66.7 %) | 39 (51.3 %) | 0.047 |